Xeris Pharmaceuticals Inc. (XERS) Misses Q4 EPS by 3c

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q4 EPS of ($0.41), $0.03 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $7.09 million versus the consensus estimate of $8.21 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• Piper Sandler: 'Amazon.com (AMZN) AMZN Looks Best Positioned'
• Celanese to sell 19% Nutrinova stake to Mitsui for $152 million